Tipranavir/Ritonavir vs. Genotypically Defined Protease Inhibitor/Ritonavir in HIV Patients (RESIST-2)
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The objective of this study is to demonstrate the safety and efficacy of tipranavir/ritonavir
versus an active control arm in highly treatment experienced Human immunodeficiency virus-1
infected patients. Patients must have a viral load > =1000 cells/mL, and genotype indicating
at least one resistance conferring protease inhibitor-mutation as determined from a
predefined panel of mutations. Any CD4+ count is acceptable.
Phase:
Phase 3
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
HIV Protease Inhibitors Protease Inhibitors Ritonavir Tipranavir